12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MoxDuo IR morphine/oxycodone: Phase III data

The double-blind, U.S. Phase III Study 009 trial in 142 patients undergoing total knee replacement surgery showed that a flexible-dose regimen of MoxDuo IR met the primary endpoint of significantly improving SPID scores from baseline over 48 hours vs. a fixed, low-dose regimen of MoxDuo IR (p<0.02). The flexible-dose regimen of MoxDuo IR...

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >